SCHEMBL4332763

SCHEMBL4332763

COC(=O)N1CCNC(C)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 3/20 0.47
CHRNA4 P43681 3/20 0.47
CHRNA3 P32297 2/20 0.47
CHRNB4 P30926 1/20 0.47
TSHR P16473 1/20 0.44
BIRC2 Q13490 2/20 0.44
HRH4 Q9H3N8 1/20 0.41
REN P00797 1/20 0.36
KDM4E B2RXH2 1/20 0.36
TP53 P04637 1/20 0.35
MDM2 Q00987 1/20 0.35
FGFR1 P11362 1/20 0.35
BMPR1A P36894 1/20 0.35
TGFBR1 P36897 1/20 0.35
ACVRL1 P37023 1/20 0.35
HAMP P81172 1/20 0.35
ACVR1 Q04771 1/20 0.35
CHRNB3 Q05901 1/20 0.34
CHRNA6 Q15825 1/20 0.34
BRPF1 P55201 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15360066 1.00 CHRNB2 (0.47) CHRNB2CHRNA4CHRNA3CHRNB4TSHR
SCHEMBL15360065 1.00 CHRNB2 (0.47) CHRNB2CHRNA4CHRNA3CHRNB4TSHR
Hydrochloric Acid SCHEMBL17560335 0.98 CHRNB2 (0.46) CHRNB2CHRNA4CHRNA3CHRNB4TSHR
Tert-Butyl Formate SCHEMBL28060431 0.85 CHRNB2 (0.36) CHRNB2CHRNA4CHRNA3CHRNB4TSHR
SCHEMBL15359953 0.83 BIRC2 (0.42) CHRNB2CHRNA4CHRNA3CHRNB4TSHR
SCHEMBL10416359 0.82 CHRNB2 (0.42) CHRNB2CHRNA4CHRNA3CHRNB4TSHR
SCHEMBL317572 0.81 BIRC2 (0.45) TSHRBIRC2HRH4KDM4EL3MBTL1
SCHEMBL952240 0.81 BIRC2 (0.45) TSHRBIRC2HRH4KDM4EL3MBTL1
SCHEMBL956554 0.81 BIRC2 (0.45) TSHRBIRC2HRH4KDM4EL3MBTL1
SCHEMBL17459853 0.80 BIRC2 (0.44) CHRNB2CHRNA4CHRNA3TSHRBIRC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3889154-A1 HETEROCYCLIC COMPOUND INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Wuhan LL Science And Technology Development Co., Ltd. (CN) 2021-10-06 EP disclosed
WO-2020135771-A1 HETEROCYCLIC COMPOUND INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 武汉朗来科技发展有限公司 2020-07-02 WO disclosed
US-7569690-B2 Process for producing oxycarbonyl-substituted piperazine derivative TORAY FINE CHEMICALS CO., LTD. (JP) 2009-08-04 US disclosed
CN-100360510-C Process for producing oxycarbonyl-substituted piperazine derivative TORAY FINECHEMICALS CO LTD (JP) 2008-01-09 CN disclosed
US-20060161003-A1 Process for producing oxycarbonyl-substituted piperazine derivative TORAY FINE CHEMICALS CO., LTD. (JP) 2006-07-20 US disclosed
CN-1681797-A Process for producing oxycarbonyl-substituted piperazine derivative TORAY FINECHEMICALS CO LTD (JP) 2005-10-12 CN disclosed
EP-1548010-A1 PROCESS FOR PRODUCING OXYCARBONYL-SUBSTITUTED PIPERAZINE DERIVATIVE Toray Fine Chemicals Co., Ltd. (JP) 2005-06-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060161003-A1 Process for producing oxycarbonyl-substituted piperazine derivative DHPS, AQP4, OGFOD1 CHRNB2 4680/4885CHRNA4 4604/4885CHRNA3 4748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.